BEAM Company Profile and Key Details
Beam Therapeutics Inc.
BEAM Stock Price Chart
Stock Price Today
Beam Therapeutics Inc. (BEAM) stock surged +0.63%, trading at $25.75 on NASDAQ, up from the previous close of $25.59. The stock opened at $25.72, fluctuating between $25.10 and $26.35 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Company Information
| Employees | 472 |
| Beta | 1.86 |
| Sales or Revenue | $377.71M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Beam Therapeutics Inc. (NASDAQ: BEAM) stock price is $25.75 in the last trading session. During the trading session, BEAM stock reached the peak price of $26.35 while $25.10 was the lowest point it dropped to. The percentage change in BEAM stock occurred in the recent session was 0.63% while the dollar amount for the price change in BEAM stock was $0.16.
The NASDAQ listed BEAM is part of Biotechnology industry that operates in the broader Healthcare sector. Beam Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Alexis Komor Ph.D.
Co-Founder
Dr. Giuseppe Ciaramella Ph.D.
Pres & Chief Scientific Officer
Mr. John M. Evans M.B.A.
Chief Executive Officer & Director
Ms. Suzanne Fleming
Chief Accounting Officer
Dr. Nicole Gaudelli Ph.D.
Co-Founder
Ms. Terry-Ann Burrell M.B.A.
Chief Financial Officer & Treasurer
Mr. Brian Riley
Senior Vice President of Technical Operations
Dr. Gopi Shanker Ph.D.
Chief Scientific Officer
Dr. Manmohan Singh Ph.D.
Chief Technology Officer
BEAM's closing price is 23.56% higher than its 52-week low of $20.84 where as its distance from 52-week high of $49.50 is -47.98%.
Number of BEAM employees currently stands at 472.
Official Website of BEAM is: https://www.beamtx.com
BEAM could be contacted at phone 857 327 8775 and can also be accessed through its website. BEAM operates from 238 Main Street, Cambridge, MA 02142, United States.
BEAM stock volume for the day was 651.16K shares. The average number of BEAM shares traded daily for last 3 months was 1.19M.
The market value of BEAM currently stands at $2.13B with its latest stock price at $25.75 and 82.81M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com